Business Context and Reporting Period
This Form 8-K filing by Perrigo Company plc (PRGO) is dated April 24, 2023. The report addresses a significant resolution regarding a long-standing tax dispute involving the Company's subsidiary, Athena Neurosciences LLC, and its former parent, Elan Corporation plc.
Key Financial Metrics and Material Changes
Tax Dispute Resolution: The U.S. Department of Treasury, Internal Revenue Service (IRS) has agreed to fully withdraw proposed adjustments regarding taxable years ending December 31, 2011, 2012, and 2013.
- Proposed Liability Avoided: The IRS previously issued Notices of Proposed Adjustments (NOPAs) totaling $843.0 million in income tax adjustments and penalties (exclusive of interest).
- Payment Status: No payment is required by Perrigo with respect to these NOPAs.
- Financial Impact: The Company plans to release previously established reserves related to this matter in the second quarter of fiscal 2023.
Background: The dispute concerned transfer pricing positions regarding the royalty rate for the drug Tysabri. The IRS had proposed a 24.7% royalty rate, whereas the Company utilized rates based on external tax advisor documentation. The resolution was achieved through the Mutual Agreement Procedure (MAP) under the U.S.-Ireland Income Tax Treaty.
Guidance, Outlook, and Management Commentary
Management Commentary: The Company states that the uncertainty regarding the tax treatment of the Tysabri royalty is now "completely resolved." The resolution constitutes a full and final settlement of the April 26, 2019 NOPAs without the need for further negotiations between competent authorities.
Outlook: The release of reserves in the second quarter of fiscal 2023 will positively impact the Company's financial results for that period. The filing includes standard forward-looking statements cautioning that actual results may differ due to various risks and uncertainties.
Investor Verification Checklist
- Verify the exact timing and amount of the reserve release in the Q2 2023 earnings report.
- Confirm that the $843.0 million figure represents the total liability avoided (tax plus penalties) exclusive of interest.
- Review the Company's Form 10-K for the year ended December 31, 2022, for a detailed discussion of remaining tax contingencies and risk factors.
- Ensure no other outstanding tax disputes exist related to the Athena/Elan acquisition or Tysabri royalties.